(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

(for nothing) Robert Oppenheimer, who is president of the American Physical Society, chairman of the technical advisers to the Atomic Energy Commission, and one of the world’s top theoretical ...

Christopher Nolan, winner of the Best Directing award and the Best Picture award for 'Oppenheimer,' at the 96th Annual Academy Awards at Ovation Hollywood on March 10, 2024 CREDIT: Rodin Eckenroth ...

Oppenheimer has become the latest Wall Street firm to raise its year-end price target for the S&P 500. Chief Market Strategist John Stoltzfus said in a report shared with MarketWatch on Monday that ...

https://www.tipranks.com/news/the-fly/sunopta-price-target-raised-to-10-from-9-at-stephens Oppenheimer raised the firm’s price target on Walmart to $90 from $81 and ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With the shares off about 30% since the surprising news of an ...

Oppenheimer raised the firm’s price target on Ingredion (INGR) to $178 from $147 and keeps an Outperform rating on the shares. The firm notes the company delivered a strong Q3 and raised its ...

Oppenheimer analyst Colin Rusch lowered the firm’s price target on Aptiv (APTV) to $83 from $147 and keeps an Outperform rating on the shares. Aptiv posted mixed Q3 results and FY24 was guided ...

“We thought better call it Big Things Films.” “Small Things Like These” was made after “Oppenheimer” but before the Oscar win, which Murphy is still processing. Work is keeping him ...

Oppenheimer raised the firm’s price target on Cboe Global Markets to $227 from $209 and keeps an Outperform rating on the shares. The firm notes Cboe is sharpening its strategic focus on ...

Shares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead asset, nomlabofusp ...

Oppenheimer analyst Timothy Horan raised the firm’s price target on AT&T to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company delivered a solid quarter ...